Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil with Lenalidomide and Dexamethasone in Multiple Myeloma
NCT01374217Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tadalafil in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Response Rate up to 6 months. Started Apr 2012; status: terminated.
02
Drugs
tadalafil
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01374217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374217.